津药药业：子公司盐酸甲氧氯普胺注射液获得药品注册证书

Core Viewpoint - The company announced that its subsidiary, Hubei Jinyao Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the registration certificate of Methoclopramide Hydrochloride Injection, which is expected to positively impact the company's performance and market expansion in the domestic formulation sector [1] Group 1 - The approved drug is classified as a Class 3 chemical drug and has passed the consistency evaluation of quality and efficacy for generic drugs [1] - The approval enhances the company's formulation product portfolio, which is anticipated to contribute positively to the company's performance [1] - The development, production, and sales of pharmaceuticals are subject to significant uncertainties due to national policies and market conditions [1]